Article
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Cancer cell - 1 Aug 2002
Shah Neil P, Nicoll John M, Nagar Bhushan, Gorre Mercedes E, Paquette Ronald L, Kuriyan John, Sawyers Charles L
Abstract excerpt
Through sequencing analysis of blood or bone marrow samples from patients with chronic myeloid leukemia, we identified BCR-ABL kinase domain mutations in 29 of 32 patients whose disease relapsed after an initial response to the tyrosine kinase inhibitor imatinib. Fifteen different amino acid substitutions affecting 13 residues in the kinase domain were found. Mutations fell into two groups-those that alter amino...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.